feedback

Course Director

David L. Rimm, MD, PhD
David L. Rimm, MD, PhD

Yale University School of Medicine
New Haven, Connecticut

Faculty

Luis A. Diaz
Luis A. Diaz, MD

Memorial Sloan Kettering Cancer Center
New York, New York

Lynette M. Sholl
Lynette M. Sholl, MD

Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME
Credit Amount:1.5 Credits
Release Date:2017-Nov-15
Expiration Date:2018-Nov-14
Estimated Time for Completion:90 minutes
Registration Required:No
Cost:Free

Activity Description and Educational Objectives

Novel cancer immunotherapies are showing remarkable clinical activity in an increasing range of solid tumors and hematologic malignancies. As the immuno-oncology (IO) landscape continues to expand, there is a growing need for biomarkers to help guide the identification of patients who are most likely to benefit from these therapies. Pathologists play an important role in cancer immunotherapy patient selection through their involvement in biomarker testing. In this unique Master Class and Practicum for pathologists, top experts examine the evolving role of IO and what this means for pathologists, exchange views on the practicalities and challenges in immunotherapy biomarker testing, and assess opportunities for further development of novel tools for predicting benefit from immunotherapies.

Upon completion of this activity, participants should be better able to:
  • Discuss the basics of cancer immunotherapy and its evolving role across the hemato-oncologic spectrum
  • Describe current and novel biomarkers for immunotherapy, and the latest evidence on their predictive utility
  • Evaluate the characteristics, benefits, and limitations of different methodologies and assays for testing PD-L1 and other current biomarkers
  • Assess the role of evaluating PD-L1 expression and other predictive biomarkers in the selection of patients for checkpoint inhibitor therapy in different tumor types and treatment settings
  • Outline promising emerging directions on the immunotherapy biomarker landscape and efforts to coordinate biomarker development and implementation
  • Implement best evidence-based practices for immunotherapy biomarker testing and interpretation of results to guide selection of patients for immunotherapy in the context of effective interdisciplinary collaboration

Target Audience

This activity has been designed to meet the educational needs of pathologists and other professionals interested in the development of biomarkers for cancer immunotherapies and their applications in the practice of pathology and laboratory medicine.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: November 15, 2017 - November 14, 2018
Time to Complete: 90 minutes

Faculty & Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity during the past 12 months.

Course Director and Moderator

David L. Rimm, MD, PhD
Professor of Pathology and Medicine (Medical Oncology)
Director, Yale Pathology Tissue Services
Yale University School of Medicine
New Haven, Connecticut

David L. Rimm, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant for Ultivue, Inc.
Advisory Board for Agendia; AstraZeneca; Bethyl Laboratories, Inc.; Biocept, Inc.; Bristol-Myers Squibb; Cell Signaling Technology, Inc.; Merck & Co., Inc.; OptraSCAN, Inc.; and PerkinElmer, Inc.

David L. Rimm, MD, PhD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: immune checkpoint inhibitors, other cancer immunotherapies or combinations, and immunotherapy biomarker testing platforms.

Faculty

Luis A. Diaz, MD
Head, Division of Solid Tumor Oncology
Memorial Sloan Kettering Cancer Center
New York, New York

Luis A. Diaz, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Merck & Co., Inc. and Personal Genome Diagnostics, Inc.
Advisory Board for Cell Design Labs, Inc.
Other Financial or Material Support from Personal Genome Diagnostics, Inc. in the form of stocks and board of director member.

Luis A. Diaz, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: immune checkpoint inhibitors, other cancer immunotherapies or combinations, and immunotherapy biomarker testing platforms.

Lynette M. Sholl, MD
Associate Pathologist
Brigham and Women’s Hospital
Associate Professor
Harvard Medical School
Boston, Massachusetts

Lynette M. Sholl, MD, has no financial interests/relationships or affiliations in relation to this activity.

Lynette M. Sholl, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: immune checkpoint inhibitors, other cancer immunotherapies or combinations, and immunotherapy biomarker testing platforms.

CME Reviewer

Vijaya R. Bhatt, MD
University of Nebraska Medical Center
Omaha, Nebraska

Vijaya R. Bhatt, MD, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director

Kadrin Wilfong, MD
PVI, PeerView Institute for Medical Education

Kadrin Wilfong, MD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit & Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership

This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported through independent educational grants from AstraZeneca and Bristol-Myers Squibb.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.


Copyright © 2000-2017, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.